|
|
||||||||
lb479 |
1 Pediatrics,
2 Medicine and Faculty St. Jean, University of Alberta, Edmonton, Canada
ABSTRACT
Rationale: Most asthma exacerbations are precipitated by airway virus infections. Understanding the inflammatory response to viruses could allow preventative immune modulating therapies. CVT-E002 (commercially available as COLD fX®) is a patented poly-furanosyl-pyranosy-saccharide-rich extract of North American ginseng. Clinical trials show that CVT-E002 prevents virus infection. Objectives: To determine whether CVT-E002 has anti-virus properties in vitro; and to understand its effects on human dendritic cells and lymphocytes. Methods: Human dendritic cells (DC) and T cells were cultured with or without virus/virus sham (RSV or RV). Flowcytometry and ELISA assays were performed. Results: RSV and RV upregulate CD25 expression in proliferating memory CD4+ T cells co-cultured with DC (n=3). DC pretreated with CVT-E002 induce increased CD25 on CD4+ T cells similar to virus infection alone. Combination of RV and CVT-E002 augments this expression (n=5). DC with CVT-E002 show increased expression of HLA-DR, CD80, CD86 (n=2). T cells and DC incubated with either RSV or RV release IFN–
, IFN-
, TNF, and IL-12 (n=1). CVT-E002 pretreatment increases this release. Without virus, CVT-E002 induces some cytokine release. Conclusion: CVT-E002 appears to induce maturation of DC and induces increased T cell proliferation with increased antiviral cytokine responses. CVT-E002 could be a useful immune modulator in the prevention of virus-induced asthma exacerbation.
| ||||||||||||||||||||||||||||||||||||||||||||